Phase 3 Trial of Ivonescimab vs Pembrolizumab in High PD-L1 Metastatic NSCLC

Summit Therapeutics is leading a multicenter, double-blind Phase 3 study comparing ivonescimab—a PD-1/VEGF bispecific antibody—with pembrolizumab in first-line therapy for metastatic NSCLC patients whose tumors express high PD-L1. The trial aims to evaluate overall survival and progression-free survival across diverse US locations.